Kestra Private Wealth Services LLC Has $3 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Kestra Private Wealth Services LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,284 shares of the medical instruments supplier’s stock after selling 173 shares during the period. Kestra Private Wealth Services LLC’s holdings in Becton, Dickinson and Company were worth $2,995,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in BDX. Jeppson Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 4.0% during the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after buying an additional 40 shares during the last quarter. Value Partners Investments Inc. increased its position in Becton, Dickinson and Company by 5.2% during the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 43 shares during the period. Dover Advisors LLC raised its stake in Becton, Dickinson and Company by 1.7% during the 3rd quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier’s stock valued at $699,000 after purchasing an additional 45 shares during the last quarter. Mendel Money Management raised its stake in Becton, Dickinson and Company by 3.0% during the 3rd quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock valued at $397,000 after purchasing an additional 45 shares during the last quarter. Finally, Phillips Wealth Planners LLC boosted its holdings in Becton, Dickinson and Company by 6.0% in the 3rd quarter. Phillips Wealth Planners LLC now owns 818 shares of the medical instruments supplier’s stock valued at $211,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $233.81 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The company has a 50-day moving average of $238.75 and a 200-day moving average of $240.71. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The company has a market capitalization of $67.55 billion, a price-to-earnings ratio of 55.41, a PEG ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.98 earnings per share. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

BDX has been the topic of several research reports. Raymond James boosted their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays boosted their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.